The Josep Carreras Leukaemia Research Institute aims to bring the cure of leukaemia and other hematologic malignancies to the patients, translating the research results into new treatments and diagnostic tools. We promote the transfer of research results building alliances at a global level, while contributing to the economic development of the territory and the sustainability of research.

To learn more about our technologies or to submit an invention report, please contact a member of our licensing team, or email innovation@carrerasresearch.org

Available technologies

EPICART

DNA methylation kit for the prediction of the response to CAR T-cell therapy.

EPICART is a risk stratification tool that employs a methylation signature that accurately predicts the treatment outcome of B-malignancy patients treated with CD19 CAR T-cell therapy.

EPICART DNA methylation kit for the prediction of the response to CAR T-cell therapy.
Find out more

HDAC7

New pharmaceutical treatment for infant t(4;11) pro-B-ALL.

Two compounds have been developed as a combinatorial therapy for the induction of HDAC7 expression, impairing t(4;11) pro-B-ALL cells’ proliferation and improving the patients’ prognosis.

HDAC7 New pharmaceutical treatment for infant t(4;11) pro-B-ALL.
Find out more

Spin-Offs

Logo Leukos Biotech

Leukos Biotech is a spin-off company from IJC, based on the research of Dr. Ruth Muñoz-Risueño, focused on developing new treatments and diagnostic tools for leukemia.

www.leukosbiotech.com
Logo OneChain Immunotherapeutics

OneChain Immunotherapeutics is a spin-off company from IJC and ICREA, based on the research led by Dr. Pablo Menéndez, with the aim to develop immunotherapies against haematological neoplasms using CAR-T candidates against different antigens.

www.onechaintx.com

Facts and Figures

Active innovation
projects
83
Spin
offs
2
Total
patents
16

success stories